Agenda

MASTERCLASS/WORKSHOPS
Monday, September 11, 2017
CONFERENCE DAY 1
Tuesday, September 12, 2017
CONFERENCE DAY 2
Wednesday, September 13, 2017

Registration and Networking Breakfast

Predicting Branded Drugs Launch Timelines in the USA and EU

Steven Robery, Ph.D., Sr. Consultant, Lifescience Dynamics

• Exercise 1: Predicting filing and approval timelines in the US; including an in-depth analysis over the last 3 years

• Exercise 2: Predicting filing and approval timelines in the EU; including an in-depth analysis of the last 3 years
• Summary and key take-aways

Networking Lunch

Ahead of the Game: When, Why and How to Run a Wargame Workshop

Philip Hart, Senior Manager, Deallus Consulting
Eugenie Joanny, Principal, Deallus Consulting

In addition to the Art of War (gaming) development, this program will help attendees structure a workshop that not

only addresses competitor tactics and initiatives, but will assist their teams in deciphering the competition’s strategic objectives and intentions.

Networking Break and Refreshments

Late Lifecyle Management – Gx/Biosimilar Issues, Intelligence Options, and Actions

Dr. Satish Kumar, Head, CI Strategies, Generics & Biosimilars, INOVIS
Dr. Baljit Singh, Managing Director and Partner, Lifesciences, INOVIS

This interactive workshop session will enable you to:

• set up a best-in-industry Gx/biosimilar RI and CI tracking program
• leverage Primary RI/CI to prepare your organization to counter the Gx/Bx threat
• understand Gx / Biosimilar product development and entry strategies
• identify potential actions to optimize launches and enforce IPR / exclusivity

This workshop session (with breakouts), will give participants first-hand insights from combined +20 years of experience helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets. This interactive session will cover issues encountered (clinical, regulatory, commercial, IP, data exclusivity), the intelligence options (what, where, why) and actions.

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Alfred Reszka, Executive Director & Head, Global Competitive Intelligence, Merck & Co.
Sue Ward, Senior Director, Worldwide Competitive Intelligence, Pfizer

Keynote: Innovation, Value and Price: Any Link?

Clive Meanwell, CEO, The Medicines Company
A discussion of the sources and methods of innovation in biopharmaceuticals and how they affect one another – or don’t.

Keynote: Ventures from the Core

Nancy Steele, Vice President, External Ventures, Pfizer Consumer Healthcare
Nancy will explore the challenges of finding new sources of growth in the Consumer Health business and how Competitive Intelligence plays a critical and unique role.

Networking & Refreshments in Exhibition Hall

Keynote: Competition is the New Black: How Competitive Intelligence is Reshaping Strategy

Jonas Pedersén, CEO and Owner, Deallus Consulting

What does a contemporary Competitive Intelligence function look like?

What can you do to set you and your organization apart from the competition to achieve success? To establish new best practices and gain and retain a market leadership position, companies and CI professionals must evolve and adapt to meet new demands. Taking into account the myriad aspects of today’s competitive biopharmaceutical environment, this session will focus on how and why companies must increase their CI savvy and move to a model of Competitive Strategy.

ROUND TABLES

(Explore hot topics in a fast-paced, interactive, and informal environment. Interested in more than one roundtable topic? We’ll have these same roundtables again tomorrow morning.)
ROUND TABLE 1
Evaluating Tools and Technologies to Support a CI Organization
Chris Ficklin, Analyst, Strategic Competitive Intelligence, Eli Lilly and Company

New sources of actionable intelligence present themselves every day.

One challenge CI organizations face is monitoring and evaluating the technology developments that can improve data analysis and visualization, add context to data, or add new sources of data altogether. This process can be very time consuming, so it is critical to the success of a group to be able to quickly and effectively discover, evaluate and make decisions on the many solutions available. This discussion will focus on best practices of tracking and evaluating technology developments, both internal and external, that can impact your CI organization.

ROUND TABLE 2
Partnerships: KOLs vs. Institutional
Archna Bhandari, Vice President, Data and Analytics, Expert System

Are Institutional Partnerships becoming more important than one-on-one KOL partnerships?

This round table will explore the growing trend of Pharma/Institution partnerships and the various aspects of these relationships and when/how best to partner.

ROUND TABLE 3
Competitive Intelligence and Business Development
David Chung, Senior Director, Strategy & Corporate Development, Jazz Pharmaceutical
ROUND TABLE 4
Integrating Research and New Product Planning
Greta Loring, Senior Director of Research and New Product Planning, Alcresta Therapeutics
ROUND TABLE 5
Manufacturing Intelligence
Kirsten Kliwinski, Senior Director, Strategic Business Intelligence, Patheon
ROUND TABLE 6
Delivering Value with Limited Resources
Neema Patel, Vice President, Marketing, Egalet
ROUND TABLE 7
How to Expand Thinking Beyond Competitive Intelligence
Michelle Maddix-Sovero, Ad Interim Head of Foresight, UCB (invited)

Networking Luncheon at Ruth’s Chris Steakhouse

PARTICIPANTS MAY CHOOSE 1 OF 4 CONCURRENT TRACKS

TRACK A

Measuring the Value of Competitive Intelligence: A Metrics Based Assessment of CI Activities

David Linson, Manager, Strategic Competitive Intelligence, Eli Lilly and Company

Measuring the value that a competitive Intelligence organization provides to a corporation is critical.

Executives that understand the impact that their CI organizations provide ensure CI is an integral part of strategic activities. In order to show value in a meaningful manner, you must measure attributes critical to the CI process and track them over time. At Eli Lilly we have determined critical attributes of CI (Quality, Insight, Impact) and are measuring our progression towards becoming a world class CI organization. Integrating customer feedback with internal CI measures provides the ability to pivot towards more impactful activities. We will discuss: how we arrived at our critical attributes, how we measure those attributes, what signals help us to pivot as an organization, and how we communicate our progression to executives.

TRACK B

Social Listening, Uncloaking the Fourth Wall: A Methodology for Turning Noise into Insights

John D Lauria, Vice President, Client Services, LCN Consulting

The fourth wall is an invisible, imagined barrier that separates actors from the audience.

While an audience can see through this wall, the convention assumes the actor performs as if they cannot. With the proliferation of social media sites, a vast opportunity exists for collecting insights on many aspects of the external environment, thereby uncloaking the fourth wall for a competitive advantage. For various reasons, many healthcare industry stakeholders have been relatively slow to maximize social media content missing opportunities for strategic insights. In this session, a process to filter these social conversations to uncover insights will be presented and demonstrated via the output from research conducted at a medical conference. Finally, the perspectives of the utility of this framework from a pharmaceutical brand stakeholder will be discussed with the audience.

Key Takeaways
1. An evaluative framework to obtain actionable social media insights to assess competitive activity
2. Tangible examples from a social media assessment conducted at a convention
3. Perspectives of the utility of this framework from a pharmaceutical brand stakeholder

TRACK C

How to Use Biomarker Intelligence to Gain Competitive Advantage

Angela Panetta, Product Manager, Adis

• Get to market faster

• Increase likelihood of approval
• Position your product in light of competitors’ strengths and weaknesses
• Identify new opportunities
• Make your organization a leader in biomarker intelligence management

TRACK D

Competitive Intelligence OUTPERFORMANCE for Bio-Pharma Industry

Vishal Dass, Vice President, WNS

Competitive Intelligence (CI), when operationalized in a vacuum, can deliver business advantage only sporadically. Fragmented implementations through localized tools and data repositories fail to give stakeholders coherent insights, while also alienating the competitive/marketing intelligence professionals from the actual decision making and strategizing processes. Collaboration and collective thinking are fast becoming critical for Bio-Pharma companies to be able to identify competitive blind spots at the right time, seize market opportunities and manage risks.
The presentation will focus on a three-pronged approach to achieve cohesive, organization-level thinking for outperformance: finding the right insights through centralized analysis of all data sources, leveraging platforms to enable integration, management and dissemination of competitive intelligence, and fostering right-time access and collaboration across organizational stakeholders.

PARTICIPANTS MAY CHOOSE 1 OF 4 CONCURRENT TRACKS

TRACK A

Redefining CI Monitoring and Conference Coverage

Muneer Ahmad, Vice President, Blueocean Market Intelligence
Benefits of adding social media and secondary analyses for a 360 approach

TRACK B

Extracting Insights from Clinical, Medical, and Regulatory Information and Opinion

Ben Weintraub, Ph.D., President, inThought Research

One of the biggest challenges facing drug developers today is information overload.

We all have access to an overwhelming amount of clinical data, market data, and thought leader opinion. What we lack is a rigorous approach to filtering through all the content on a daily basis, and making sure that the important bits of knowledge are captured in the appropriate places. Dr. Weintraub will discuss data sources such as medical conferences, company presentations, press releases, and drug databases, but more importantly will present a framework for tagging and storing the information and insights so that it is accessible and convenient for a large team. Dr. Weintraub will provide examples of the challenges of healthcare competitive intelligence as well as some predictions for the future in Alzheimer’s disease, multiple sclerosis, and atopic dermatitis.

TRACK C

The Endpoint is Just the Beginning

Beau Bush, President and Founder, OZMOSI

Today’s pharmaceutical industry is continually evolving the way we treat patients and develop treatments.

It is now more important than ever to not only understand your marketplace, but also how it is evolving and how your competitors’ strategize to provide a meaningful treatment at launch. Examining trends over time as well as across therapeutic categories provides a clear pathway to success in developing new products while also uncovering insights for portfolio planning and goals.

TRACK D

Right Patient, Right Time, Right Test: How More Efficient Diagnostic Testing can Reduce Patient Leakage

Ryan Keeling, COO, Diaceutics

Supporting a more efficient diagnostic testing process to drive better integration between the targeted therapy and its associated test:

where does the potential for patient leakage exist and what can be done to ensure the right patients are being identified so they can benefit from the right therapies at the right time?
• Inefficiencies in the diagnostic testing landscape, such as long turnaround times or slow adoption and uptake of testing can lead to missed opportunities
• Investing in specific areas to address the seamless integration of both the test and the therapy can serve as a competitive advantage with companion diagnostics
• Understanding the competitive landscape, where companies are investing and how focused attention on getting the testing process working optimally can drive strategic commercial decisions

PARTICIPANTS MAY CHOOSE 1 OF 4 CONCURRENT TRACKS

TRACK A

Bridging Traditional Pharma and Startups Technology Companies to Conduct Added Value Research Initiatives with Limited Budgets

Eduardo Fernandez, VP of Business Operations and Consumer Brands, Exeltis

Exeltis, a specialty pharma with unique consumer products, defined an implemented a research initiative for its Women’s Fertility product called

Pregnitude which promotes developed to help women having difficulty getting pregnant. The initiative was articulated through a partnership with Ovia Health, a Fertility and Maternity App, that allowed to implement the research through their technology platform.

The research was based on supplying Pregnitude to 120 voluntarily enrolled participants and tracking a large number of variable and data points for 6 months through the app.
These type of research initiative is highly scalable, lower cost, and has the potential to gather increased number of quality data points, and participants engagement is higher.

TRACK B

Pharmaceutical CI: Practice and Potential

Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics
Karthik Subramanian, Commercial Manager, Portfolio & Licensing, Clarivate Analytics

This session will provide an insight into current Pharma CI practice, trends and best practice. This will include some/all of the following:

1) State of the nation: feedback/benchmarks on pharmaceutical CI
2) Current practice: typical CI offerings and challenges
3) Best practice
4) Future outlook

TRACK C

An All-Source Approach to Evaluating Manufacturing Capacity

Aaron Derdowski, Senior Engagement Manager, Proactive Worldwide

Estimations of manufacturing capacities are often a critical part of assessing the degree of competitive threat from new or generic drugs.

In this session, Dr. Derdowski will review how Proactive Worldwide uses multiple sources of intelligence to provide accurate estimates of manufacturing capacity. Attendees will gain an understanding of how overhead imagery, import/export bills of lading, manufacturing equipment assessments and primary research can be combined to yield impactful, accurate estimations of competitor capabilities.

TRACK D

Supercharge Your CI with Pharma Intelligence and Informatics

Michael Hay, Head of Intelligence Products, Informa

Fear of missing out: It’s what keeps us up at night.

The ability to monitor the competitive landscape has become increasingly complex. To effectively stay on top of developments in the ever-evolving Pharma industry, one must integrate and analyze multiple data sources, which can be a manual and time-consuming process. This presentation will demonstrate the power of informatics to rapidly marry different datasets, such as investigator location, trial activity, and epidemiology data from Informa Pharma Intelligence, building the full picture necessary to support your CI needs and arm you with actionable insight in a fast-moving market.

Networking & Refreshments in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 4 CONCURRENT TRACKS

TRACK A

The New Normal of Healthcare

Shri Parikh, Vice President, Surgical Sales and Marketing, Mölnlycke Health Care

TRACK B

Multi-Source Integrated and Collaborative Intelligence: A Case Study

Erik Glitman, CEO, Fletcher/CSI, LLC

TRACK C

The Roadmap to a High Performance Partnership in Executing CI

Samer Eid, Director, Corporate Development, Merck & Co.

In this presentation we will discuss a roadmap that hopefully pave the way towards building an effective relationship between the CI consulting agency, the Pharma CI professional, and the key internal stakeholders/teams.

By presenting a number of examples from case-studies, we will illustrate the possibilities of producing a “High Performance Partnership” that not only focuses on the current deliverable but ultimately strives to build a long-term relationship where the external agency becomes an extension of the internal team. The presentation will touch upon the barriers that could be encountered and will highlight best practices that are key drivers to an effective partnership with the ultimate goal of achieving product/asset differentiation and informed decision making about resource deployment based on sound CI evidence.

TRACK D

TBD

PARTICIPANTS MAY CHOOSE 1 OF 3 CONCURRENT TRACKS

TRACK A

Panel Discussion: CI - Destination and Journey

Learn from recognized leaders in the Pharma CI industry including their background, leadership journey, critical skills to be successful, and potential career paths.
Moderator:
Cheri Oban, Director of CI, Genentech
Panelists:
Rebecca Derwin, Director, Competitive Intelligence and Analytics, EMD Serono
Maureen Nail, Director, Competitive Intelligence, Pfizer
Katherine Kim, Associate Director, Business Analysis, Pharmacyclics

TRACK B

Panel Discussion: Evolving Analytics Capabilities and their Application in CI and Decision Making

Moderator:
Marcus Droege, Ph.D., MBA, Global Head, Knowledge & Strategic Intelligence, Celgene Corporation
Panelists:
Darien Kadens, Head of Market Intelligence - Latin America, Lupin Pharmaceuticals
Jacob Lai, Sr. Director, Market Planning, Versartis
Nick Mordwinkin, Associate Director, Corporate Strategy, Ultragenyx Pharmaceutical

TRACK C

Panel Discussion: Competitive Insights into New Product and Business Planning and Development

Moderator:
Omar Gaya, Senior Director, Strategic Analysis & Corporate Strategy, Regeneron Pharmaceuticals
Panelists:
Sharlene Cirillo, Executive Director of Marketing, Churchill Pharmaceuticals
Sandra Graham-Mason, Associate Director, Oncology Marketing, Eisai
Anne Marie Robertson, Vice President Marketing, Helsinn Group

Evening Socializing Events! Reception & Networking

Registration & Networking Breakfast in Exhibition Hall

ROUND TABLES

(Explore hot topics in a fast-paced, interactive, and informal environment.)
ROUND TABLE 1
Evaluating Tools and Technologies to Support a CI Organization
Chris Ficklin, Analyst, Strategic Competitive Intelligence, Eli Lilly and Company

New sources of actionable intelligence present themselves every day.

One challenge CI organizations face is monitoring and evaluating the technology developments that can improve data analysis and visualization, add context to data, or add new sources of data altogether. This process can be very time consuming, so it is critical to the success of a group to be able to quickly and effectively discover, evaluate and make decisions on the many solutions available. This discussion will focus on best practices of tracking and evaluating technology developments, both internal and external, that can impact your CI organization.

ROUND TABLE 2
Partnerships: KOLs vs. Institutional
Archna Bhandari, Vice President, Data and Analytics, Expert System

Are Institutional Partnerships becoming more important than one-on-one KOL partnerships?

This round table will explore the growing trend of Pharma/Institution partnerships and the various aspects of these relationships and when/how best to partner.

ROUND TABLE 3
Competitive Intelligence and Business Development
David Chung, Senior Director, Strategy & Corporate Development, Jazz Pharmaceutical
ROUND TABLE 4
Integrating Research and New Product Planning
Greta Loring, Senior Director of Research and New Product Planning, Alcresta Therapeutics
ROUND TABLE 5
Manufacturing Intelligence
Kirsten Kliwinski, Senior Director, Strategic Business Intelligence, Patheon
ROUND TABLE 6
Delivering Value with Limited Resources
Neema Patel, Vice President, Marketing, Egalet
ROUND TABLE 7
How to Expand Thinking Beyond Competitive Intelligence
Michelle Maddix-Sovero, Ad Interim Head of Foresight, UCB (invited)

PARTICIPANTS MAY CHOOSE 1 OF 4 CONCURRENT TRACKS

TRACK A

Best Practices & Planning Tools to Maximize ROI for Scientific Conferences

Bruno Larvol, President, Larvol
Indra Sethy-Coraci, Director, Immunology Therapeutic Area Competitive Intelligence, Boehringer Ingelheim

• Preparing for scientific conferences incurs significant costs for CI departments, which are under increased pressure to justify their spending.

• The timing of data release (e.g., late-breaking abstracts) and the need for real-time data analysis to generate customized planners presents a significant challenge. Data rights and compliance considerations must also be taken into account.
• Conference organizers as well as third-party solution-providers are tackling these issues with novel technologies and platforms, including mobile apps, automatic data indexing, and natural language processing (NLP).
• We will present best practices from top pharmaceutical firms and provide a demo of our newly-launched solution.

TRACK B

How to Double Your CI Resources to Get Your Next Promotion

Sabih Beck, Competitive Intelligence Lead, Roche
Salvador Carlucci, Head of Competitive Intelligence, Atacana Group

Two of pharma’s most successful CI professionals reveal at last, 3 expert secrets to have a greater business impact in your organization and to be recognized for the value you will create.

If you have been struggling with getting more CI budget, CI headcounts or recognition then you need to attend this talk because it will give you actionable strategies to implement right away in any organization.

TRACK C

Building an Intelligence Culture

Heath Gross, CEO, Sedulo Group

The first step in building an effective CI program is establishing and cultivating an intelligence culture.

An intelligence culture is one in which each member of the organization understands, appreciates and participates in the intelligence process. During this session we will present both practical and theoretical aspects of intelligence culture as it relates to:

-Breaking down information silos and replacing them with tools for collaboration and information sharing
-Growing culture to grow the budget; an intelligence culture values intelligence and insights and is will to pay for them
-“Culture eats strategy for breakfast” – Having a sound strategy isn’t enough, you need the will of the organization to execute

TRACK D

The Importance of Your Competitive Intelligence Team Brand

Mary Ann Sarao, Director, Global Competitive Intelligence, Bayer Consumer Health

Networking & Refreshments in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Solving a CI Challenge

Invigorate your innovation by solving a simulated CI project in a real-world environment. Participants will work in teams guided by veteran CI leaders. Background, tools, techniques, and strategy will be provided. At the end, each group will deliver a final presentation. This will energize you!
Team 1:
    Jonas Pedersén, CEO and Owner, Deallus Consulting
    Cyrus Arman, Director of Business Analysis & Information/ Global Head of Competitive Intelligence, Amgen
Team 2:
    Rafaat Rahmani, BBA, MBA, President, Lifescience Dynamics
    Steven Robery, Ph.D., Sr. Consultant, Lifescience Dynamics
    Marjorie Norman, Director, Worldwide Competitive Intelligence, Pfizer
Team 3:
    Marc Limacher, MBA, Founder and CEO, INOVIS
    Hari Patel, Group Manager, Genentech (Invited)
    Dr. Baljit Singh, Managing Director and Partner, Lifesciences, INOVIS
Team 4:
    Dave Alderman, President, Molekule Consulting
    Dr. Daniel Pascheles, CEO, Molekule Consulting
    Friederike Wirtz-Brugger, Director, CI Pharma Products, Sanofi
Team 5:
    Jamie Denison-Pender, CEO, Prescient Healthcare Group
    Venu Gopalakrishnan, Executive Director, Business Analytics, PTC Therapeutics
    Mark Little, President & Global Head of Strategic Planning, Prescient Healthcare Group

TRACK B

The Un-Conference Experience

You've got questions, our experts have answers. We’ve gathered a seasoned panel of experts that will answer any questions you might have, walk you through any solutions, or share experiences. This session encourages open dialogue so don't be shy, bring up whatever topic you'd like to discuss.
Moderator:
    Chris Bogan, Chief Executive Officer, Best Practices, LLC
Panelists:
    Chet Kitchen, Director, Global Competitive Intelligence, Merck
    Michael Kostelansky, Director Market Research, Business Development, Daiichi Sankyo, Inc.
    Randall Pinchuk, Sr. Director, Strategy and Corporate Development, Pacira Pharmaceuticals
    Amanda Wagner, Vice President, Product Planning & Program Management, Concert Pharmaceuticals

Networking Lunch at Ruth’s Chris Steakhouse

Announcement of Raffle Prize Winners and Announcement of Recipient of Pharma CI’s Award of the Year: “Most Innovative Approach to CI”

Keynote: Connecting for Insight in Building a Strong Corporate Brand Identity

Paul Bould, Divisional Vice President, Marketing Intelligence Global Marketing Organization, Abbott
Why insights should sit alongside all other functions (incl. Marketing).

Presentations by the “Solving a CI Challenge” Groups

Presentation

Closing by Chairpersons

Alfred Reszka, Executive Director & Head, Global Competitive Intelligence, Merck & Co.
Sue Ward, Senior Director, Worldwide Competitive Intelligence, Pfizer

Conference Concludes